PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2128159
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2128159
Endometrial Cancer Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
Growth Factors of endometrial cancer Market
The global endometrial cancer market was valued at USD 2.66 billion in 2025 and is projected to grow from USD 3.01 billion in 2026 to USD 7.90 billion by 2034, registering a CAGR of 12.84% during the forecast period. North America dominated the global market with a 46.61% market share in 2025, supported by advanced healthcare infrastructure, increasing adoption of immunotherapy, widespread biomarker testing, and favorable reimbursement policies.
Endometrial cancer is one of the most common gynecologic malignancies affecting women worldwide. The market includes therapies for early-stage, advanced, recurrent, and metastatic disease, with treatment strategies increasingly shifting toward precision medicine and immunotherapy-based combinations. Pharmaceutical companies are actively investing in research and development, clinical trials, and regulatory approvals to improve patient outcomes and expand treatment options. The growing incidence of the disease, coupled with advancements in molecular diagnostics, continues to create strong growth opportunities for the industry.
Growing Adoption of Immunotherapy and Precision Medicine Drives Market Growth
The market is experiencing significant transformation as healthcare providers increasingly adopt biomarker-guided therapies for personalized treatment. PD-1 inhibitors, targeted therapies, and combination regimens are becoming the preferred treatment options for advanced and recurrent endometrial cancer. Expanded regulatory approvals for immunotherapy combinations are enabling more patients to access innovative treatments, thereby accelerating overall market growth.
Rising Development of Novel Immuno-Oncology Therapies Emerges as a Key Market Trend
One of the major trends shaping the endometrial cancer market is the growing pipeline of innovative immuno-oncology therapies, antibody-drug conjugates, and targeted medicines. Pharmaceutical companies are expanding clinical development programs to address unmet needs among patients with recurrent or biomarker-defined disease. The increasing focus on HER2-positive, dMMR/MSI-H, and pMMR patient populations is supporting the transition toward personalized cancer care and improving long-term survival outcomes.
Market Drivers
The rising incidence of endometrial cancer remains the primary growth driver for the market. Factors such as aging populations, obesity, diabetes, and metabolic disorders are contributing to increasing diagnosis rates worldwide. As more patients require advanced treatment, hospitals and oncology centers are expanding access to molecular testing, immunotherapy, and targeted medicines. Continuous product approvals and label expansions further strengthen market demand by providing physicians with more effective treatment options.
Market Restraints
Despite rapid innovation, the high cost of advanced therapies continues to limit market expansion. Immunotherapy combinations, targeted drugs, biomarker testing, and long-term patient monitoring significantly increase treatment expenses. In developing countries and cost-sensitive healthcare systems, reimbursement limitations often delay the adoption of premium therapies, restricting patient access despite demonstrated clinical benefits.
Market Opportunities
The expansion of biomarker-guided treatment strategies presents significant growth opportunities for market participants. Precision medicine enables physicians to select therapies based on molecular characteristics, improving treatment response and patient survival. Pharmaceutical companies are increasingly developing targeted therapies for HER2-expressing, MSI-H, dMMR, and pMMR patient populations, creating new commercial opportunities while supporting personalized oncology care.
Segmentation Analysis
Based on drug class, PD-1 inhibitors dominated the market in 2025 due to their proven clinical effectiveness in advanced and recurrent endometrial cancer. Their broad regulatory approvals, strong survival outcomes, and increasing use alongside chemotherapy continue to strengthen segment growth. The PD-L1 inhibitors segment is expected to witness the fastest expansion during the forecast period.
By cancer type, endometrioid adenocarcinoma accounted for the largest market share because it represents the majority of diagnosed endometrial cancer cases worldwide. The large patient population and broad use of surgery, chemotherapy, immunotherapy, and hormonal therapy support its leading position.
Based on therapy, chemotherapy remained the dominant treatment segment in 2025, as platinum-taxane regimens continue to serve as the standard first-line treatment backbone, even when combined with immunotherapy. However, immunotherapy is expected to register the highest growth due to increasing approvals and wider physician acceptance.
Hospital pharmacies dominated the distribution channel segment owing to the hospital-based administration of chemotherapy and immunotherapy treatments requiring specialist supervision.
Regional Outlook
North America led the global endometrial cancer market with a valuation of USD 1.24 billion in 2025. The region benefits from strong oncology infrastructure, high diagnosis rates, widespread biomarker testing, and rapid adoption of innovative immunotherapies. The U.S. remains the largest contributor to regional revenue.
Europe represents the second-largest regional market, supported by expanding regulatory approvals, national cancer programs, and increasing use of immunotherapy-based treatment combinations. Germany and the U.K. continue to drive regional growth through improved access to advanced oncology care.
Asia Pacific is projected to experience substantial growth due to its expanding patient population, improving healthcare infrastructure, increasing cancer awareness, and rising availability of modern oncology treatments. China, Japan, and India are expected to remain key growth markets throughout the forecast period.
Latin America and the Middle East & Africa are anticipated to record steady growth as healthcare investments increase, cancer diagnosis improves, and access to advanced therapies gradually expands across emerging economies.
Competitive Landscape
The global endometrial cancer market is moderately consolidated, with major companies investing heavily in research, biomarker-based drug development, regulatory approvals, and strategic collaborations. Leading companies include Merck & Co., Inc., Eisai Co., Ltd., GSK plc, AstraZeneca PLC, Pfizer Inc., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Accord Healthcare Limited, and Bristol Myers Squibb Company. Ongoing clinical trials, product launches, and label expansions continue to strengthen competition across the market.
Recent Industry Developments
In April 2026, BioNTech announced positive Phase 2 results for trastuzumab pamirtecan in HER2-expressing advanced endometrial cancer. During the same month, Utepreva LLC launched an FDA-cleared endometrial sampling device designed to improve early diagnosis. In August 2024, GSK received U.S. FDA approval for Jemperli combined with carboplatin and paclitaxel for advanced or recurrent endometrial cancer, further expanding immunotherapy treatment options.
Conclusion
The global endometrial cancer market is expected to witness strong growth through 2034, driven by rising disease incidence, increasing adoption of precision medicine, expanding biomarker testing, and continuous innovation in immunotherapy and targeted therapies. With growing investments in research and development, favorable regulatory approvals, and broader access to personalized treatment approaches, the market is well-positioned for sustained expansion between 2026 and 2034.
Segmentation By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Region
By Drug Class * PD-1 Inhibitors
- Platinum Compounds
- Taxanes
- VEGFR/Multikinase Inhibitors
- Progestins
- PD-L1 Inhibitors
- Others
By Cancer Type * Endometrioid Adenocarcinoma
- Serous Endometrial Carcinoma
- Clear Cell Carcinoma
- Carcinosarcoma
- Others
By Age Group * Pediatric
- Adults
By Therapy * Chemotherapy
- Immunotherapy
- Targeted Therapy
- Hormonal Therapy
- Others
By Route of Administration * Oral
- Parenteral
By Distribution Channel * Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
- Specialty Pharmacies
By Region * North America (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 3.5. Market Challenges
4. Key Insights
- 4.1. Prevalence of Endometrial Cancer, By Countries/Region, 2025
- 4.2. New Product Launches, By Key Players
- 4.3. Overview of Regulatory Scenario, By Key Regions/ Countries
- 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.5. Pipeline Analysis, By Key Players
5. Global Endometrial Cancer Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug Class
- 5.1.1. PD-1 Inhibitors
- 5.1.2. Platinum Compounds
- 5.1.3. Taxanes
- 5.1.4. VEGFR/Multikinase Inhibitors
- 5.1.5. Progestins
- 5.1.6. PD-L1 Inhibitors
- 5.1.7. Others
- 5.2. Market Analysis, Insights and Forecast - By Cancer Type
- 5.2.1. Endometrioid Adenocarcinoma
- 5.2.2. Serous Endometrial Carcinoma
- 5.2.3. Clear Cell Carcinoma
- 5.2.4. Carcinosarcoma
- 5.2.5. Others
- 5.3. Market Analysis, Insights and Forecast - By Age Group
- 5.3.1. Pediatric
- 5.3.2. Adults
- 5.4. Market Analysis, Insights and Forecast - By Therapy
- 5.4.1. Chemotherapy
- 5.4.2. Immunotherapy
- 5.4.3. Targeted Therapy
- 5.4.4. Hormonal Therapy
- 5.4.5. Others
- 5.5. Market Analysis, Insights and Forecast - By Route of Administration
- 5.5.1. Oral
- 5.5.2. Parenteral
- 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.6.1. Hospital Pharmacies
- 5.6.2. Drug Stores & Retail Pharmacies
- 5.6.3. Online Pharmacies
- 5.6.4. Specialty Pharmacies
- 5.7. Market Analysis, Insights and Forecast - Region
- 5.7.1. North America
- 5.7.2. Europe
- 5.7.3. Asia Pacific
- 5.7.4. Latin America
- 5.7.5. Middle East & Africa
6. North America Endometrial Cancer Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug Class
- 6.1.1. PD-1 Inhibitors
- 6.1.2. Platinum Compounds
- 6.1.3. Taxanes
- 6.1.4. VEGFR/Multikinase Inhibitors
- 6.1.5. Progestins
- 6.1.6. PD-L1 Inhibitors
- 6.1.7. Others
- 6.2. Market Analysis, Insights and Forecast - By Cancer Type
- 6.2.1. Endometrioid Adenocarcinoma
- 6.2.2. Serous Endometrial Carcinoma
- 6.2.3. Clear Cell Carcinoma
- 6.2.4. Carcinosarcoma
- 6.2.5. Others
- 6.3. Market Analysis, Insights and Forecast - By Age Group
- 6.3.1. Pediatric
- 6.3.2. Adults
- 6.4. Market Analysis, Insights and Forecast - By Therapy
- 6.4.1. Chemotherapy
- 6.4.2. Immunotherapy
- 6.4.3. Targeted Therapy
- 6.4.4. Hormonal Therapy
- 6.4.5. Others
- 6.5. Market Analysis, Insights and Forecast - By Route of Administration
- 6.5.1. Oral
- 6.5.2. Parenteral
- 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.6.1. Hospital Pharmacies
- 6.6.2. Drug Stores & Retail Pharmacies
- 6.6.3. Online Pharmacies
- 6.6.4. Specialty Pharmacies
- 6.7. Market Analysis, Insights and Forecast - By Country
- 6.7.1. U.S.
- 6.7.2. Canada
7. Europe Endometrial Cancer Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug Class
- 7.1.1. PD-1 Inhibitors
- 7.1.2. Platinum Compounds
- 7.1.3. Taxanes
- 7.1.4. VEGFR/Multikinase Inhibitors
- 7.1.5. Progestins
- 7.1.6. PD-L1 Inhibitors
- 7.1.7. Others
- 7.2. Market Analysis, Insights and Forecast - By Cancer Type
- 7.2.1. Endometrioid Adenocarcinoma
- 7.2.2. Serous Endometrial Carcinoma
- 7.2.3. Clear Cell Carcinoma
- 7.2.4. Carcinosarcoma
- 7.2.5. Others
- 7.3. Market Analysis, Insights and Forecast - By Age Group
- 7.3.1. Pediatric
- 7.3.2. Adults
- 7.4. Market Analysis, Insights and Forecast - By Therapy
- 7.4.1. Chemotherapy
- 7.4.2. Immunotherapy
- 7.4.3. Targeted Therapy
- 7.4.4. Hormonal Therapy
- 7.4.5. Others
- 7.5. Market Analysis, Insights and Forecast - By Route of Administration
- 7.5.1. Oral
- 7.5.2. Parenteral
- 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.6.1. Hospital Pharmacies
- 7.6.2. Drug Stores & Retail Pharmacies
- 7.6.3. Online Pharmacies
- 7.6.4. Specialty Pharmacies
- 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.7.1. U.K.
- 7.7.2. Germany
- 7.7.3. France
- 7.7.4. Italy
- 7.7.5. Spain
- 7.7.6. Scandinavia
- 7.7.7. Rest of Europe
8. Asia Pacific Endometrial Cancer Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug Class
- 8.1.1. PD-1 Inhibitors
- 8.1.2. Platinum Compounds
- 8.1.3. Taxanes
- 8.1.4. VEGFR/Multikinase Inhibitors
- 8.1.5. Progestins
- 8.1.6. PD-L1 Inhibitors
- 8.1.7. Others
- 8.2. Market Analysis, Insights and Forecast - By Cancer Type
- 8.2.1. Endometrioid Adenocarcinoma
- 8.2.2. Serous Endometrial Carcinoma
- 8.2.3. Clear Cell Carcinoma
- 8.2.4. Carcinosarcoma
- 8.2.5. Others
- 8.3. Market Analysis, Insights and Forecast - By Age Group
- 8.3.1. Pediatric
- 8.3.2. Adults
- 8.4. Market Analysis, Insights and Forecast - By Therapy
- 8.4.1. Chemotherapy
- 8.4.2. Immunotherapy
- 8.4.3. Targeted Therapy
- 8.4.4. Hormonal Therapy
- 8.4.5. Others
- 8.5. Market Analysis, Insights and Forecast - By Route of Administration
- 8.5.1. Oral
- 8.5.2. Parenteral
- 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.6.1. Hospital Pharmacies
- 8.6.2. Drug Stores & Retail Pharmacies
- 8.6.3. Online Pharmacies
- 8.6.4. Specialty Pharmacies
- 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.7.1. China
- 8.7.2. Japan
- 8.7.3. India
- 8.7.4. Southeast Asia
- 8.7.5. Australia
- 8.7.6. Rest of Asia Pacific
- 8.8. Market Analysis, Insights and Forecast - By Drug Class
- 8.8.1. PD-1 Inhibitors
- 8.8.2. Platinum Compounds
- 8.8.3. Taxanes
- 8.8.4. VEGFR/Multikinase Inhibitors
- 8.8.5. Progestins
- 8.8.6. PD-L1 Inhibitors
- 8.8.7. Others
- 8.9. Market Analysis, Insights and Forecast - By Cancer Type
- 8.9.1. Endometrioid Adenocarcinoma
- 8.9.2. Serous Endometrial Carcinoma
- 8.9.3. Clear Cell Carcinoma
- 8.9.4. Carcinosarcoma
- 8.9.5. Others
- 8.10. Market Analysis, Insights and Forecast - By Age Group
- 8.10.1. Pediatric
- 8.10.2. Adults
- 8.11. Market Analysis, Insights and Forecast - By Therapy
- 8.11.1. Chemotherapy
- 8.11.2. Immunotherapy
- 8.11.3. Targeted Therapy
- 8.11.4. Hormonal Therapy
- 8.11.5. Others
- 8.12. Market Analysis, Insights and Forecast - By Route of Administration
- 8.12.1. Oral
- 8.12.2. Parenteral
- 8.13. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.13.1. Hospital Pharmacies
- 8.13.2. Drug Stores & Retail Pharmacies
- 8.13.3. Online Pharmacies
- 8.13.4. Specialty Pharmacies
- 8.14. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.14.1. Brazil
- 8.14.2. Mexico
- 8.14.3. Rest of Latin America
9. Middle East & Africa Endometrial Cancer Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug Class
- 9.1.1. PD-1 Inhibitors
- 9.1.2. Platinum Compounds
- 9.1.3. Taxanes
- 9.1.4. VEGFR/Multikinase Inhibitors
- 9.1.5. Progestins
- 9.1.6. PD-L1 Inhibitors
- 9.1.7. Others
- 9.2. Market Analysis, Insights and Forecast - By Cancer Type
- 9.2.1. Endometrioid Adenocarcinoma
- 9.2.2. Serous Endometrial Carcinoma
- 9.2.3. Clear Cell Carcinoma
- 9.2.4. Carcinosarcoma
- 9.2.5. Others
- 9.3. Market Analysis, Insights and Forecast - By Age Group
- 9.3.1. Pediatric
- 9.3.2. Adults
- 9.4. Market Analysis, Insights and Forecast - By Therapy
- 9.4.1. Chemotherapy
- 9.4.2. Immunotherapy
- 9.4.3. Targeted Therapy
- 9.4.4. Hormonal Therapy
- 9.4.5. Others
- 9.5. Market Analysis, Insights and Forecast - By Route of Administration
- 9.5.1. Oral
- 9.5.2. Parenteral
- 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.6.1. Hospital Pharmacies
- 9.6.2. Drug Stores & Retail Pharmacies
- 9.6.3. Online Pharmacies
- 9.6.4. Specialty Pharmacies
- 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.7.1. GCC
- 9.7.2. South Africa
- 9.7.3. Rest of Middle East & Africa
10. Competitive Analysis
- 10.1. Global Market Share Analysis (2025)
- 10.2. Company Profiles
- 10.2.1. Merck & Co., Inc.
- 10.2.2. Eisai Co., Ltd.
- 10.2.3. GSK plc
- 10.2.4. AstraZeneca PLC
- 10.2.5. Pfizer Inc.
- 10.2.6. Fresenius Kabi AG
- 10.2.7. Hikma Pharmaceuticals PLC
- 10.2.8. Teva Pharmaceutical Industries Ltd.
- 10.2.9. Accord Healthcare Limited
- 10.2.10. Bristol Myers Squibb Company
List of Tables
- Table 1: Global Endometrial Cancer Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 2: Global Endometrial Cancer Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
- Table 3: Global Endometrial Cancer Market Revenue (USD billion) Forecast, by Age Group 2021-2034
- Table 4: Global Endometrial Cancer Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
- Table 5: Global Endometrial Cancer Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 6: Global Endometrial Cancer Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 7: Global Endometrial Cancer Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 8: North America Endometrial Cancer Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 9: North America Endometrial Cancer Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
- Table 10: North America Endometrial Cancer Market Revenue (USD billion) Forecast, by Age Group 2021-2034
- Table 11: North America Endometrial Cancer Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
- Table 12: North America Endometrial Cancer Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 13: North America Endometrial Cancer Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 14: North America Endometrial Cancer Market Revenue (USD billion) Forecast, by Country, 2021-2034
- Table 15: Europe Endometrial Cancer Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 16: Europe Endometrial Cancer Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
- Table 17: Europe Endometrial Cancer Market Revenue (USD billion) Forecast, by Age Group 2021-2034
- Table 18: Europe Endometrial Cancer Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
- Table 19: Europe Endometrial Cancer Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 20: Europe Endometrial Cancer Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 21: Europe Endometrial Cancer Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
- Table 22: Asia Pacific Endometrial Cancer Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 23: Asia Pacific Endometrial Cancer Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
- Table 24: Asia Pacific Endometrial Cancer Market Revenue (USD billion) Forecast, by Age Group 2021-2034
- Table 25: Asia Pacific Endometrial Cancer Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
- Table 26: Asia Pacific Endometrial Cancer Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 27: Asia Pacific Endometrial Cancer Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 28: Asia Pacific Endometrial Cancer Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
- Table 29: Latin America Endometrial Cancer Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 30: Latin America Endometrial Cancer Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
- Table 31: Latin America Endometrial Cancer Market Revenue (USD billion) Forecast, by Age Group 2021-2034
- Table 32: Latin America Endometrial Cancer Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
- Table 33: Latin America Endometrial Cancer Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 34: Latin America Endometrial Cancer Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 35: Latin America Endometrial Cancer Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
- Table 36: Middle East & Africa Endometrial Cancer Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 37: Middle East & Africa Endometrial Cancer Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
- Table 38: Middle East & Africa Endometrial Cancer Market Revenue (USD billion) Forecast, by Age Group 2021-2034
- Table 39: Middle East & Africa Endometrial Cancer Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
- Table 40: Middle East & Africa Endometrial Cancer Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 41: Middle East & Africa Endometrial Cancer Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 42: Middle East & Africa Endometrial Cancer Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Endometrial Cancer Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Endometrial Cancer Market Value Share (%), by Drug Class, 2025 & 2034
- Figure 3: Global Endometrial Cancer Market Value Share (%), by Cancer Type, 2025 & 2034
- Figure 4: Global Endometrial Cancer Market Value Share (%), by Age Group, 2025 & 2034
- Figure 5: Global Endometrial Cancer Market Value Share (%), by Therapy, 2025 & 2034
- Figure 6: Global Endometrial Cancer Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 7: Global Endometrial Cancer Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 8: Global Endometrial Cancer Market Value Share (%), by Region, 2025 & 2034
- Figure 9: North America Endometrial Cancer Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 10: North America Endometrial Cancer Market Value Share (%), by Drug Class, 2025
- Figure 11: North America Endometrial Cancer Market Value (USD billion), by Cancer Type, 2025 & 2034
- Figure 12: North America Endometrial Cancer Market Value Share (%), by Cancer Type, 2025
- Figure 13: North America Endometrial Cancer Market Value (USD billion), by Age Group 2025 & 2034
- Figure 14: North America Endometrial Cancer Market Value Share (%), by Age Group 2025
- Figure 15: North America Endometrial Cancer Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 16: North America Endometrial Cancer Market Value Share (%), by Therapy, 2025
- Figure 17: North America Endometrial Cancer Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 18: North America Endometrial Cancer Market Value Share (%), by Route of Administration, 2025
- Figure 19: North America Endometrial Cancer Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 20: North America Endometrial Cancer Market Value Share (%), by Distribution Channel, 2025
- Figure 21: North America Endometrial Cancer Market Value (USD billion), by Country, 2025 & 2034
- Figure 22: North America Endometrial Cancer Market Value Share (%), by Country, 2025
- Figure 23: Europe Endometrial Cancer Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 24: Europe Endometrial Cancer Market Value Share (%), by Drug Class, 2025
- Figure 25: Europe Endometrial Cancer Market Value (USD billion), by Cancer Type, 2025 & 2034
- Figure 26: Europe Endometrial Cancer Market Value Share (%), by Cancer Type, 2025
- Figure 27: Europe Endometrial Cancer Market Value (USD billion), by Age Group 2025 & 2034
- Figure 28: Europe Endometrial Cancer Market Value Share (%), by Age Group 2025
- Figure 29: Europe Endometrial Cancer Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 30: Europe Endometrial Cancer Market Value Share (%), by Therapy, 2025
- Figure 31: Europe Endometrial Cancer Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 32: Europe Endometrial Cancer Market Value Share (%), by Route of Administration, 2025
- Figure 33: Europe Endometrial Cancer Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 34: Europe Endometrial Cancer Market Value Share (%), by Distribution Channel, 2025
- Figure 35: Europe Endometrial Cancer Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 36: Europe Endometrial Cancer Market Value Share (%), by Country/ Sub-region, 2025
- Figure 37: Asia Pacific Endometrial Cancer Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 38: Asia Pacific Endometrial Cancer Market Value Share (%), by Drug Class, 2025
- Figure 39: Asia Pacific Endometrial Cancer Market Value (USD billion), by Cancer Type, 2025 & 2034
- Figure 40: Asia Pacific Endometrial Cancer Market Value Share (%), by Cancer Type, 2025
- Figure 41: Asia Pacific Endometrial Cancer Market Value (USD billion), by Age Group 2025 & 2034
- Figure 42: Asia Pacific Endometrial Cancer Market Value Share (%), by Age Group 2025
- Figure 43: Asia Pacific Endometrial Cancer Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 44: Asia Pacific Endometrial Cancer Market Value Share (%), by Therapy, 2025
- Figure 45: Asia Pacific Endometrial Cancer Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 46: Asia Pacific Endometrial Cancer Market Value Share (%), by Route of Administration, 2025
- Figure 47: Asia Pacific Endometrial Cancer Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 48: Asia Pacific Endometrial Cancer Market Value Share (%), by Distribution Channel, 2025
- Figure 49: Asia Pacific Endometrial Cancer Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 50: Asia Pacific Endometrial Cancer Market Value Share (%), by Country/ Sub-region, 2025
- Figure 51: Latin America Endometrial Cancer Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 52: Latin America Endometrial Cancer Market Value Share (%), by Drug Class, 2025
- Figure 53: Latin America Endometrial Cancer Market Value (USD billion), by Cancer Type, 2025 & 2034
- Figure 54: Latin America Endometrial Cancer Market Value Share (%), by Cancer Type, 2025
- Figure 55: Latin America Endometrial Cancer Market Value (USD billion), by Age Group 2025 & 2034
- Figure 56: Latin America Endometrial Cancer Market Value Share (%), by Age Group 2025
- Figure 57: Latin America Endometrial Cancer Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 58: Latin America Endometrial Cancer Market Value Share (%), by Therapy, 2025
- Figure 59: Latin America Endometrial Cancer Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 60: Latin America Endometrial Cancer Market Value Share (%), by Route of Administration, 2025
- Figure 61: Latin America Endometrial Cancer Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 62: Latin America Endometrial Cancer Market Value Share (%), by Distribution Channel, 2025
- Figure 63: Latin America Endometrial Cancer Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 64: Latin America Endometrial Cancer Market Value Share (%), by Country/ Sub-region, 2025
- Figure 65: Middle East & Africa Endometrial Cancer Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 66: Middle East & Africa Endometrial Cancer Market Value Share (%), by Drug Class, 2025
- Figure 67: Middle East & Africa Endometrial Cancer Market Value (USD billion), by Cancer Type, 2025 & 2034
- Figure 68: Middle East & Africa Endometrial Cancer Market Value Share (%), by Cancer Type, 2025
- Figure 69: Middle East & Africa Endometrial Cancer Market Value (USD billion), by Age Group 2025 & 2034
- Figure 70: Middle East & Africa Endometrial Cancer Market Value Share (%), by Age Group 2025
- Figure 71: Middle East & Africa Endometrial Cancer Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 72: Middle East & Africa Endometrial Cancer Market Value Share (%), by Therapy, 2025
- Figure 73: Middle East & Africa Endometrial Cancer Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 74: Middle East & Africa Endometrial Cancer Market Value Share (%), by Route of Administration, 2025
- Figure 75: Middle East & Africa Endometrial Cancer Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 76: Middle East & Africa Endometrial Cancer Market Value Share (%), by Distribution Channel, 2025
- Figure 77: Middle East & Africa Endometrial Cancer Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 78: Middle East & Africa Endometrial Cancer Market Value Share (%), by Country/ Sub-region, 2025
- Figure 79: Global Endometrial Cancer Market Share (%), by Company, 2025
